| Autor: |
Manoj V. Murhekar, Muthusamy Santhosh Kumar, P. Kamaraj, Siraj Ahmed Khan, Ramesh Reddy Allam, Pradip Barde, Bhagirathi Dwibedi, Suman Kanungo, Uday Mohan, Suman Sundar Mohanty, Subarna Roy, Vivek Sagar, Deepali Savargaonkar, Babasaheb V. Tandale, Roshan Kamal Topno, C.P. Girish Kumar, R. Sabarinathan, Sailaja Bitragunta, Gagandeep Singh Grover, P.V.M. Lakshmi, Chandra Mauli Mishra, Provash Sadhukhan, Prakash Kumar Sahoo, S.K. Singh, Chander Prakash Yadav, Rajesh Kumar, Shanta Dutta, G.S. Toteja, Nivedita Gupta, Sanjay M. Mehendale, T. Karunakaran, Annamma Jose, D. Augustine, C. Govindhasamy, T. Daniel Rajasekar, A. Jeyakumar, A. Suresh, P. Ashok Kumar, R. Sivakumar, J.W. Banerjee John |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
International Journal of Infectious Diseases, Vol 100, Iss , Pp 455-460 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
1201-9712 |
| DOI: |
10.1016/j.ijid.2020.08.084 |
| Popis: |
Introduction: India introduced a hepatitis-B (HB) vaccine in the Universal Immunization Program in 2002–2003 on a pilot basis, expanded to ten states in 2007–2008 (phase-1), and the entire country in 2011–2012 (phase-2). We tested sera from a nationally representative serosurvey conducted duing 2017, to estimate the seroprevalence of different markers of HB infection among children aged 5–17 years in India and to assess the impact of vaccination. Methods: We tested sera from 8273 children for different markers of HB infection and estimated weighted age-group specific seroprevalence of children who were chronically infected (HBsAg and anti-HBc positive), and immune due to past infection (anti-HBc positive and HBsAg negative), and having serological evidence of HB vaccination (only anti-HBs positive). We compared the prevalence of serological markers among children born before (aged 11–17 years) and after (aged 5-10 years) introduction of HB-vaccine from phase-1 states. Results: Among children aged 5–8 years, 1.1% were chronic carriers, 5.3% immune due to past infection, and 23.2% vaccinated. The corresponding proportions among children aged 9–17 years were 1.1%, 8.0%, and 12.0%, respectively. In phase-1 states, children aged 5–10 years had a significantly lower prevalence of anti-HBc (4.9% vs. 7.6%, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
